ChEMBL ligand: CHEMBL2158685 (Abc-294640, Abc294640, ABC 294640, Opaganib)
sphingosine kinase 1/Sphingosine kinase 1 in Human [ChEMBL: CHEMBL4394] [GtoPdb: 2204] [UniProtKB: Q9NYA1] There should be some charts here, you may need to enable JavaScript!
sphingosine kinase 2/Sphingosine kinase 2 in Human [ChEMBL: CHEMBL3023] [GtoPdb: 2205] [UniProtKB: Q9NRA0] There should be some charts here, you may need to enable JavaScript!

DB	Assay description	Assay Type	Standard value	Standard parameter	Original value	Original units	Original parameter	Reference
sphingosine kinase 1/Sphingosine kinase 1 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL4394] [GtoPdb: 2204] [UniProtKB: Q9NYA1]
ChEMBL	Inhibition of recombinant human SphK1 using NBD-sphingosine as substrate after 2 hrs in presence of ATP by HPLC method	B	4	pIC50	>100000	nM	IC50	Bioorg Med Chem (2017) 25: 3046-3052 [PMID:28408190]
sphingosine kinase 2/Sphingosine kinase 2 in Human (target type: SINGLE PROTEIN) [ChEMBL: CHEMBL3023] [GtoPdb: 2205] [UniProtKB: Q9NRA0]
ChEMBL	Inhibition of SK2 (unknown origin)	B	5	pKi	10000	nM	Ki	J Med Chem (2016) 59: 965-984 [PMID:26780304]
ChEMBL	Inhibition of SK2 (unknown origin)	B	5	pKi	10000	nM	Ki	Medchemcomm (2013) 4: 1394-1399 [PMID:24396570]
ChEMBL	Inhibition of SphK2 (unknown origin)	B	5	pKi	10000	nM	Ki	Bioorg Med Chem Lett (2015) 25: 4956-4960 [PMID:25862200]
ChEMBL	Inhibition of human recombinant SphK2 expressed in Sf9 cells assessed as radiolabeled products using 10 uM sphingosine and 10 uM gamma[32P]ATP by liquid scintillation counting	B	5.01	pKi	9800	nM	Ki	J Med Chem (2015) 58: 1879-1899 [PMID:25643074]
ChEMBL	Inhibition of SPHK2 (unknown origin)	B	5.01	pKi	9800	nM	Ki	Bioorg Med Chem (2016) 24: 3218-3230 [PMID:27255176]
ChEMBL	Inhibition of recombinant human SPHK2 using sphingosine as substrate by ADP-Quest assay	B	5.01	pKi	9800	nM	Ki	J Med Chem (2017) 60: 3933-3957 [PMID:28406646]
ChEMBL	Inhibition of recombinant human full-length N-terminal His-tagged SK2 expressed in baculovirus infected Sf9 insect cells using NBD-Sph as substrate measured after 2 hrs by fluorescence based HPLC analysis	B	5.01	pKi	9800	nM	Ki	J Med Chem (2019) 62: 3658-3676 [PMID:30889352]
ChEMBL	Inhibition of recombinant human N-terminal His-tagged full length SphK2 expressed in baculovirus infected Sf9 cells using C17-sphingosine as substrate incubated for 2 hrs by ADQ Quest assay	B	5.01	pKi	9800	nM	Ki	Eur J Med Chem (2020) 206: 112713-112713 [PMID:32919113]
ChEMBL	Inhibition of recombinant human N-terminal His-tagged Sphk2 (2 to 593 residues) expressed in Escherichia coli using varying level of sphingosine as substrate by ADP quest assay	B	5.01	pKi	9800	nM	Ki	Eur J Med Chem (2021) 212: 113121-113121 [PMID:33445156]
ChEMBL	Binding affinity to Sphk2 (unknown origin) assessed as inhibition constant	B	5.01	pKi	9800	nM	Ki	J Med Chem (2022) 65: 893-921 [PMID:33539089]
ChEMBL	Binding affinity to recombinant SphK2 (unknown origin) ADP Quest assay system	B	5.01	pKi	9800	nM	Ki	J Med Chem (2022) 65: 935-954 [PMID:33970631]
ChEMBL	Inhibition of human recombinant SphK2 using NBD-sphingosine as substrate after 2 hrs by HPLC analysis	B	5.01	pKi	9800	nM	Ki	Bioorg Med Chem Lett (2012) 22: 6817-6820 [PMID:22321213]
ChEMBL	Inhibition of SphK2 (unknown origin) assessed as inhibition constant	B	5.01	pKi	9800	nM	Ki	Eur J Med Chem (2021) 213: 113164-113164 [PMID:33454547]
ChEMBL	Inhibition of purified human SphK2 assessed as inhibition of formation of [33P]-S1P after 50 mins by scintillation counting	B	5.01	pKi	9800	nM	Ki	Bioorg Med Chem Lett (2013) 23: 4608-4616 [PMID:23845219]
ChEMBL	Competitive inhibition of human recombinant SphK2 assessed as NBD-S1P formation using NBD-Sph as substrate by HPLC analysis	B	5.01	pKi	9800	nM	Ki	J Med Chem (2014) 57: 5509-5524 [PMID:24471412]
GtoPdb	-	-	5.01	pKi	9800	nM	Ki	J Pharmacol Exp Ther (2010) 333: 129-39 [PMID:20061445]
ChEMBL	Inhibition of recombinant human SphK2 using NBD-sphingosine as substrate after 2 hrs in presence of ATP by HPLC method	B	4.22	pIC50	60000	nM	IC50	Bioorg Med Chem (2017) 25: 3046-3052 [PMID:28408190]

ChEMBL data shown on this page come from version 34:

Zdrazil B, Felix E, Hunter F, Manners EJ, Blackshaw J, Corbett S, de Veij M, Ioannidis H, Lopez DM, Mosquera JF, Magarinos MP, Bosc N, Arcila R, Kizilören T, Gaulton A, Bento AP, Adasme MF, Monecke P, Landrum GA, Leach AR. (2024). The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods. Nucleic Acids Res., 52(D1). DOI: 10.1093/nar/gkad1004. [EPMCID:10767899] [PMID:37933841]
Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, Bellis L, Overington JP. (2015) 'ChEMBL web services: streamlining access to drug discovery data and utilities.' Nucleic Acids Res., 43(W1). DOI: 10.1093/nar/gkv352. [EPMCID:25883136]